Vijaya Diagnostic Centre reported a 36.4% increase in net profit for the third quarter of fiscal 2025, rising to ₹35.2 crore, compared to ₹25.8 crore in the same quarter last year.
| Company | Value | Change | %Change |
|---|
The company’s revenue grew by 27.4% year-on-year, reaching ₹169 crore, up from ₹132.7 crore in Q3 FY24.
EBITDA surged 59%, standing at ₹67 crore against ₹42.2 crore in the previous year’s corresponding quarter.
The company’s EBITDA margin improved to 39.7%, compared to 31.8% in Q3 FY24.
The company saw a 27.6% increase in total tests, which rose to 3.68 million in Q3, compared to 2.88 million in Q3 FY24. The growth trend continued in the nine-month period, with total tests reaching 11.00 million, a 29.0% increase year-on-year.
Total footfall also showed strong growth, up 19.3% YoY at 1.05 million in Q3, compared to 0.88 million in Q3 FY24. For 9MFY25, footfall increased by 22.1%, totaling 3.14 million.
The company’s tests per footfall increased by 6.9% YoY in Q3, reaching 3.52 tests per footfall, up from 3.29 tests per footfall in Q3 FY24.
Excluding preventive health checks (PH), total tests grew by 20.0% YoY, while footfall excluding PH increased by 15.0% YoY.
Despite a slight decline in average realization per test (down 0.2% YoY to ₹460), the average realization per footfall saw a 6.7% increase, reaching ₹1,616 in Q3 FY25.
The company’s wellness segment continued to show positive growth, contributing 14.1% of total revenue in Q3, up from 12.2% in the same quarter last year, reflecting a 47.1% increase in wellness share.
Shares of Vijaya Diagnostics ended 4.9% lower today at ₹1,025.95 on the BSE.
